On October 23rd, 2014, we updated our
By continuing to use LinkedIn’s SlideShare service, you agree to the revised terms, so please take a few minutes to review them.
Action at 42 nicotine receptor Partial agonist/antagonist Releases lower amounts of dopamine intobrain than smoke • Reduces withdrawal • Not as addictive as smokeBlocks nicotine from binding to receptor • Prevents reward of smoking
Varenicline 12 semaines + si succès encore 12 semaines varenicline ou placebo80 717060 5050 12 sem + placebo40 12+12 sem3020100 Communiqué de presse du 15 nov 2005, Pfizer
Increased CV risk with smoking cessation drug varenicline: New meta-analysis Sources1. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated withvarenicline: a systematic review and meta-analysis. CMAJ 2011. Available at:http://www.cmaj.ca2. Hays JT. Varenicline for smoking cessation: Is it a heartbreaker? CMAJ 2011.